656 related articles for article (PubMed ID: 29032239)
1. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
[TBL] [Abstract][Full Text] [Related]
2. The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder.
Meyer A; Ghandour R; Bergman A; Castaneda C; Wosnitzer M; Hruby G; Benson M; McKiernan J
J Urol; 2014 Sep; 192(3):696-701. PubMed ID: 24657802
[TBL] [Abstract][Full Text] [Related]
3. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
[TBL] [Abstract][Full Text] [Related]
4. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
[TBL] [Abstract][Full Text] [Related]
6. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
8. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.
Nielsen N; Wrist Lam G; Fabrin K; Holt P; Thind PO; Jensen JB
Scand J Urol; 2019 Aug; 53(4):213-216. PubMed ID: 31174449
[No Abstract] [Full Text] [Related]
9. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
10. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
[TBL] [Abstract][Full Text] [Related]
11. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder.
Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A
Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614
[TBL] [Abstract][Full Text] [Related]
12. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
[TBL] [Abstract][Full Text] [Related]
14. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival.
Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A
Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752
[No Abstract] [Full Text] [Related]
15. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
[TBL] [Abstract][Full Text] [Related]
16. Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Pak JS; Haas CR; Anderson CB; DeCastro GJ; Benson MC; McKiernan JM
Urol Oncol; 2021 Nov; 39(11):787.e9-787.e15. PubMed ID: 33865688
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder.
Park K; Lee HJ; Kim TU; Ryu H; Ki YK; Hong YJ; Nam JK
Asia Pac J Clin Oncol; 2023 Dec; 19(6):739-746. PubMed ID: 37461246
[TBL] [Abstract][Full Text] [Related]
18. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
20. Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer.
Leibowitz-Amit R; Israel A; Gal M; Atenafu EA; Symon Z; Portnoy O; Laufer M; Dotan Z; Ramon J; Avni D; Fridman E; Berger R
Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):790-796. PubMed ID: 27498850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
